PL2041129T3 - Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne - Google Patents

Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne

Info

Publication number
PL2041129T3
PL2041129T3 PL07809909T PL07809909T PL2041129T3 PL 2041129 T3 PL2041129 T3 PL 2041129T3 PL 07809909 T PL07809909 T PL 07809909T PL 07809909 T PL07809909 T PL 07809909T PL 2041129 T3 PL2041129 T3 PL 2041129T3
Authority
PL
Poland
Prior art keywords
human protein
pharmaceutical use
tyrosine phosphatase
phosphatase inhibitors
inhibitors
Prior art date
Application number
PL07809909T
Other languages
English (en)
Inventor
Jeffrey Lyle Gray
Cynthia Monesa Clark
Kande Amarasinghe
Mathew Brian Maier
Ryan Nichols
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38704718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2041129(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of PL2041129T3 publication Critical patent/PL2041129T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07809909T 2006-06-27 2007-06-27 Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne PL2041129T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81682506P 2006-06-27 2006-06-27
EP07809909.0A EP2041129B1 (en) 2006-06-27 2007-06-27 Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use
PCT/US2007/014824 WO2008002571A2 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
PL2041129T3 true PL2041129T3 (pl) 2014-11-28

Family

ID=38704718

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07809909T PL2041129T3 (pl) 2006-06-27 2007-06-27 Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
PL14166121T PL2803663T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14166121T PL2803663T3 (pl) 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne

Country Status (23)

Country Link
US (3) US7589212B2 (pl)
EP (3) EP2041129B1 (pl)
JP (1) JP5201740B2 (pl)
KR (1) KR101157844B1 (pl)
CN (1) CN101506204B (pl)
AU (1) AU2007265455B2 (pl)
BR (1) BRPI0713349A2 (pl)
CA (1) CA2656915C (pl)
CO (1) CO6150143A2 (pl)
CY (1) CY1115588T1 (pl)
DK (2) DK2803663T3 (pl)
ES (2) ES2510674T3 (pl)
HK (1) HK1203960A1 (pl)
IL (1) IL196130A (pl)
MX (1) MX2009000290A (pl)
NZ (1) NZ574405A (pl)
PL (2) PL2041129T3 (pl)
PT (2) PT2803663T (pl)
RU (1) RU2430101C2 (pl)
SI (1) SI2041129T1 (pl)
TR (1) TR201802280T4 (pl)
WO (1) WO2008002571A2 (pl)
ZA (1) ZA200900558B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
DK2385763T3 (en) * 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
NZ610230A (en) * 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
RU2507597C2 (ru) * 2012-05-23 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы никорандилом
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
RU2526466C1 (ru) * 2013-04-04 2014-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10900319B2 (en) 2017-12-14 2021-01-26 Exacta-Frac Energy Services, Inc. Cased bore straddle packer
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
WO2021086904A1 (en) 2019-10-29 2021-05-06 Aerpio Pharmaceuticals, Inc. Small molecule activators of tie-2
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69332197T2 (de) * 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
EP0642353A1 (en) * 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
JPH106346A (ja) * 1996-06-19 1998-01-13 Takemoto Oil & Fat Co Ltd プラスチック成形型の製造方法及びプラスチック成形型
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
WO2000065088A2 (en) 1999-04-26 2000-11-02 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU5147700A (en) * 1999-05-19 2000-12-05 Amgen, Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
WO2001016097A1 (en) 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6589758B1 (en) * 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
EP1409540A2 (en) 2000-09-27 2004-04-21 The Procter & Gamble Company Melanocortin receptor ligands
AR038703A1 (es) * 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AU2003222127A1 (en) * 2002-03-29 2003-10-13 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
KR20060073626A (ko) * 2003-09-17 2006-06-28 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 고휘도 방전 램프
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas

Also Published As

Publication number Publication date
AU2007265455A1 (en) 2008-01-03
SI2041129T1 (sl) 2014-11-28
EP3287455A1 (en) 2018-02-28
JP5201740B2 (ja) 2013-06-05
EP2803663A1 (en) 2014-11-19
AU2007265455B2 (en) 2011-11-10
CO6150143A2 (es) 2010-04-20
EP2041129B1 (en) 2014-09-03
IL196130A0 (en) 2009-09-22
ZA200900558B (en) 2012-04-24
KR20090024296A (ko) 2009-03-06
BRPI0713349A2 (pt) 2012-03-06
IL196130A (en) 2014-04-30
RU2009102537A (ru) 2010-08-10
DK2803663T3 (en) 2018-03-05
MX2009000290A (es) 2009-03-16
WO2008002571B1 (en) 2008-04-17
US7589212B2 (en) 2009-09-15
HK1129388A1 (en) 2009-11-27
HK1203960A1 (en) 2015-11-06
ES2660571T3 (es) 2018-03-23
NZ574405A (en) 2012-01-12
US20090227639A1 (en) 2009-09-10
RU2430101C2 (ru) 2011-09-27
CN101506204A (zh) 2009-08-12
US20070299116A1 (en) 2007-12-27
PT2041129E (pt) 2014-10-08
PL2803663T3 (pl) 2018-05-30
CA2656915C (en) 2012-08-07
US8188125B2 (en) 2012-05-29
PT2803663T (pt) 2018-02-28
US8338615B2 (en) 2012-12-25
JP2009542660A (ja) 2009-12-03
CY1115588T1 (el) 2017-01-04
CN101506204B (zh) 2012-05-30
EP2803663B1 (en) 2017-11-29
US20120077853A1 (en) 2012-03-29
TR201802280T4 (tr) 2018-03-21
AU2007265455A2 (en) 2009-05-21
KR101157844B1 (ko) 2012-06-22
WO2008002571A2 (en) 2008-01-03
WO2008002571A3 (en) 2008-02-14
EP2041129A2 (en) 2009-04-01
CA2656915A1 (en) 2008-01-03
DK2041129T3 (da) 2014-10-13
ES2510674T3 (es) 2014-10-21

Similar Documents

Publication Publication Date Title
PL2041129T3 (pl) Czynniki hamujące ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
PL2038265T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania
PT2592072T (pt) Inibidores de proteína tirosina fosfatase humana e sua utilização
GB0625659D0 (en) Therapeutic compounds and their use
IL198591A0 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA200903598B (en) Lipase variants for pharmaceutical use
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
GB0719803D0 (en) Therapeutic compounds and their use
IL204442A (en) Inhibitors of atpase-0fif, medicinal preparations containing them and their use
GB0719644D0 (en) Therapeutic compounds and their use
PL2036882T3 (pl) Związki o jonach obojnaczych i ich zastosowanie
IL194751A0 (en) Drugs and uses
EP2224928A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
GB0724251D0 (en) Therapeutic compounds and their use
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL204889A0 (en) Novel seh inhibitors and their use
GB0722680D0 (en) Therapeutic compounds and their use
IL199477A (en) Medicinal preparations containing colesblem or colesblem hydrochloride and their use
IL206891A0 (en) Therapeutic inhibitors of pai-1 function and methods of their use
EP2217068A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP2209376A4 (en) NEW SEH-HEMMER AND ITS USE
GB0614586D0 (en) Pharmaceutical Formulation
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF